CORPORATE PRESENTATION

1537 NW 65th Avenue

Plantation, FL 33313 USA

Phone: (954) 321-8988

Fax: (954) 321-9778

info@ReceptoPharm.com

www.ReceptoPharm.com

OVERVIEW

ReceptoPharm is an innovative biopharmaceutical drug

discovery company developing proprietary therapeutic

protein products and providing specialized contract

services catering to small and start-up biotechnology

companies.

OV

ER

VIE

W

Introduction

ReceptoPharm is a biopharmaceutical drug discovery company based in Plantation,

Florida. The Company is primarily engaged in the discovery and development of novel

and off-patent peptide technologies for the prevention and treatment of disease in

humans. In 2008, ReceptoPharm began offering a full range of contract services

catering to small and start-up biotechnology companies.

Drug Development

The emphasis of ReceptoPharm's approach to drug discovery and the development of new therapeutic agents is

based upon specialized receptor-binding proteins found in nature. With its' large volume of research and preclinical

data ReceptoPharm believes it has identified a number of therapeutic products that have the capability to provide

significant benefits for patients with neurological, immunological, autoimmune and viral conditions.

CRO Services

ReceptoPharm offers a full range of contract services catering to start-up and small biotechnology companies. These

services include pre-production studies, contract manufacturing services, US & EU regulatory support, and quality

systems/GMP certification.

OV

ER

VIE

W

Management Team

ReceptoPharm’s management is comprised of a team of highly experienced

businesspeople and scientists with over 100 years of combined industry expertise.

Name

Rik J. Deitsch Chairman and Chief Executive Officer, Nutra Pharma Corporation

Paul F. Reid, Ph.D. Chief Executive Officer, ReceptoPharm

Laurence N. Raymond, Ph.D. Chief Scientific Officer, ReceptoPharm

Harold Rumph Director, ReceptoPharm

OV

ER

VIE

W

Advisors

ReceptoPharm maintains collaborative and research relationships with a number of

noted academic researchers associated with the National Institutes of Health (NIH),

Harvard University, Massachusetts General Hospital, Yale University, Baylor College of

Medicine and Soochow University.

Name Organization

Dorothy Bray, Ph.D. ImmunoClin Ltd.

Zouhair M. Atassi, Ph.D., D.Sc. Baylor College of Medicine

Zheng-Hong Qin, MD, Ph.D.Harvard University / Massachusetts General Hospital (Boston,

Massachusetts) and Soochow University (Suzhou, China)

Thomas L. Lentz, MD Yale University

DRUG DISCOVERY

ReceptoPharm conducts research into a number of

products with applications for neurological,

immunological, autoimmune and viral conditions. The

Company’s leading drug candidates are RPI-MN and

RPI-78M.

DR

UG

DIS

CO

VE

RY

Drug Discovery Overview

ReceptoPharm is an innovative biopharmaceutical drug discovery company developing

proprietary therapeutic protein products for the billion-dollar biologics market. The

Company has two leading products: RPI-MN and RPI-78M.

RPI-MN

RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases

as encephalitis and Human Immunodeficiency Virus (HIV). It is being developed first for the treatment of HIV.

RPI-78M

RPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other

neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and Amyotrophic Lateral

Sclerosis (ALS).

RPI-78M and RPI-MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine

receptors) but have the opposite effect. In a specific chemical process unique to ReceptoPharm, the drugs are

created through a process of chemical modification.

DR

UG

DIS

CO

VE

RY

Benefits of RPI-MN and RPI-78M

RPI-MN and RPI-78M possess several desirable properties as drugs:

1. They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells.

This means that patients cannot overdose.

2. They display no serious adverse side effects following years of investigations in humans and animals.

3. They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has

been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.

4. They are easy to administer.

5. RPI-78M can be administered orally -- a first for a biologic MS drug. This will present MS patients with additional

quality of life benefits by eliminating the requirement for routine injections.

DR

UG

DIS

CO

VE

RY

Specific Benefits of RPI-MN

Benefits of ReceptoPharm’s HIV/AIDs Treatment

RPI-MN Fuzeon by Roche/Trimeris

Mutations are not Created Mutations are Created

Relatively Inexpensive Very Expensive – Twice Current Therapies

No Significant Adverse Side Effects Adverse Side Effects Present – Some Severe

Long Shelf Life Limited Shelf Life

Patient Does Not Develop Resistance Patient Develops Immune Resistance

Easy to Manufacture Difficult Manufacturing Leads to Limited Use

DR

UG

DIS

CO

VE

RY

Specific Benefits of RPI-78M

Benefits of ReceptoPharm’s Multiple Sclerosis (MS) Treatment

RPI-78M Competitive Drugs

Disease Progress Stops Disease Progression Only Slows

Patient Condition Improves No Claims Against Patient Improvement

No Significant Adverse Side Effects Adverse Side Effects Present – Some Severe

Long Shelf Life Limited Shelf Life

Resistant to Heat Requires Refrigeration

Patient Does Not Develop Resistance Patient Develops Immune Resistance

Improves Quality of Life No Evidence for Quality of Life Improvement

DR

UG

DIS

CO

VE

RY

Cobroxin Overview

Cobroxin is the first over-the-counter pain reliever clinically proven to treat Stage 2

(moderate to severe) chronic pain.

Cobroxin, which was developed by ReceptoPharm, was launched in August 2009 and will be available as

an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and

as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional Benefits to Cobroxin Include:

• All Natural

• Non-Addictive

• Non-Narcotic

• Non-Opiate

• More Potent than Morphine

• Long Lasting

DR

UG

DIS

CO

VE

RY

Cobroxin Market Potential

Pain is the single most common reason patients seek medical care and accounts for half

of all physician office visits in the United States.

According to the American Pain Foundation, each year, more than 25 million people in the United States

experience acute pain as a result of injury or surgery. Additionally, more than 50 million people in the

United States are affected by ongoing chronic pain.

The Cobroxin Advantage:

1. Makes potent pain relief accessible to:

• People without healthcare insurance (42 million)

• People without prescription coverage

• People afraid of opiate side effects

• People subject to drug screening for work

• People for whom OTC NSAIDs didn’t work and are just living with the pain

• Doctors afraid to prescribe opiates

2. Targets consumers not well-served by current products

DR

UG

DIS

CO

VE

RY

Research & Development Pipeline

ReceptoPharm's research and development pipeline consists of several novel therapies

in various stages of development to prevent and/or treat Multiple Sclerosis (MS),

Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN), Herpes,

Rheumatoid Arthritis (RA) and Pain.

Abbreviations: Preclinical (PC), Phase 1 (P-I),

Phase 2 (P-II), Phase 3 (P-III)

DR

UG

DIS

CO

VE

RY

Published Research

Cobratoxin Inhibits Pain-Evoked Discharge of Neurons in Thalamic Parafascicular Nucleus in Rats:

Involvement of cholinergic and serotonergic systems // Toxicon (April 2009)

Alpha Cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature leading to

Its Development for This Application // Critical Reviews™ in Immunology (Volume 27 / Issue 4 2007)

Analgesic Effects of Receptin, a Chemically Modified Cobratoxin from Thailand Cobra Venom //

Neuroscience Bulletin (September 2006)

Amelioration of Acute and Relapsing Stages of the Experimental Allergic Encephalomyelitis by

Cobra Toxins // Biomedical Sciences Instrumentation (June 2006)

A Long-Form a-Neurotoxin from Cobra Venom Produces Potent Opioid-Independent Analgesia //

Acta Pharmacologica Sinica (April 2006)

A Short-Chain a-Neurotoxin from Naja naja atra Produces Potent Cholinergic-Dependent Analgesia

// Neuroscience Bulletin (March 2006)

CONTRACT RESEARCH SERVICES

ReceptoPharm has installed the pathways to

develop, produce and supply clinical material for

Phase I and II studies at the highest levels. In 2008,

the Company began offering services catering to

small and start-up biotechnology companies.

CO

NT

RA

CT

RE

SE

AR

CH

SE

RV

ICE

S

Partnering with ReceptoPharm

As a clinical stage company specializing in biologics, ReceptoPharm has cleared many

of the hurdles that face emerging biotech companies. Below are the top reasons that

companies choose to partner with ReceptoPharm as its CRO:

1. Therapeutic experience encompassing infectious disease, autoimmune conditions, neurological disorders and

oncology indications.

2. A renowned team of scientists, led by Dr. Paul Reid, specializing in human and veterinary regulatory affairs for the

United States, Canada, and Europe, and drug applications (pre IND, IND and Orphan), drug production, new drug

development, clinical trial design, patient monitoring, and experimental design.

3. Significant investment in establishing a production facility to meet US and EU standards, including the installation

of quality systems to meet GMP standards and ISO Class 5 certification.

CO

NT

RA

CT

RE

SE

AR

CH

SE

RV

ICE

S

A Global View on Drug Development

ReceptoPharm prides itself on taking a global view on drug development; whether it’s

preparing submissions, protocols, formulations, or organizing clinical trials

internationally.

ReceptoPharm has invested heavily in establishing its own production facility to meet US and EU standards,

including the installation of quality systems to meet GMP standards. Its commitment to maintaining the highest quality

standards can now be used as a resource by other biopharmaceutical companies.

CO

NT

RA

CT

RE

SE

AR

CH

SE

RV

ICE

S

Top-Rated Drug Production Facilities

Establishing and maintaining a qualified drug production facility can represent a

significant drain on a small company’s resources.

ReceptoPharm understands that its investment in manufacturing and its first-hand knowledge in drug discovery and

development can be very valuable assets to small companies that do not have these resources or capabilities in-

house. Working with ReceptoPharm through its ISO class 5 and GMP certified facilities will allow these companies to

avoid considerable clinical development expenses and allow them to focus on a more important task, expeditiously

getting their products to the next stage.

CO

NT

RA

CT

RE

SE

AR

CH

SE

RV

ICE

S

Pre-Production Studies

� Stability Studies

� Formulation

� Adventitious Viral Testing

� Preservative Efficacy Testing

� Assay Development/Potency Testing

� Methods Development

Contract Manufacturing Services

US & EU Regulatory Support

� FDA Drug Applications, IND Preparation

� EU Submissions, IMPD Preparation

Quality Systems/GMP Certification

� Installation of Quality Systems Using Our SOPs

� GMP Audits

� GMP Training

� QA Function

� IQ/OQ/PQ

� Validations (Equipment and Processes)

Sterile Filling Capabilities

ReceptoPharm can manually fill a variety of drug

products for your clinical development projects in the

US and EU. While ReceptoPharm specializes in

biologics, including MAbs, natural, recombinant and

synthetic proteins, it can also prepare and fill

pharmaceutical products in its ISO class 5

cleanroom facilities.

� Drug Formulation

� ISO 5 Sterile Filling Suite, Single and Multi-Dose

Liquids for Injection

� Clinical Trial Supplies to FDA & EU Requirements

� Packaging and Shipment to Sites

� Release Testing and Certification

CONTACT RECEPTOPHARM

1537 NW 65th Avenue

Plantation, FL 33313 USA

Phone: (954) 321-8988

Fax: (954) 321-9778

info@ReceptoPharm.com

www.ReceptoPharm.com